RSP Systems has completed its Series B at a total amount of US$15.5 million to accelerate regulatory approval and manufacturing of the GlucoBeam, a novel device that offers convenient and accurate noninvasive glucose monitoring for people with diabetes. RSP Systems A/S has received an additional US$3.3 million in financing from several key investors. The Series B closed at US$15.5 million, bringing RSP Systems’ total financing to approximately US$28.4 million.
“We are pleased to have gained further support from investors to expedite the market launch of our device. The continuous interest from the investment community confirms the widespread need for an accurate and simple to use non-invasive glucose monitoring device improving the lives of people with diabetes,” said Andreas Jenne, CEO of RSP Systems. “
RSP’s device, the GlucoBeam, uses a beam of light to painlessly and accurately measure glucose levels. It is the result of over 12 years of research and clinical development by RSP’s team of world-class engineers and specialists, who have adapted well-respected Raman spectroscopy technology for daily use in a consumer device.
For more information, please contact RSP Systems’ CSO Anders Weber, PhD at email@example.com